1. Home
  2. Live Updates
  3. Roche group

Live Breaking News & Updates on Roche group

Stay informed with the latest breaking news from Roche group on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Roche group and stay connected to the pulse of your community

Global Biobetters Market Analysis to 2034 by Drug Class,

Dublin, April 09, 2024 (GLOBE NEWSWIRE) -- The

United-states , Japan , Germany , Canada , South-korea , United-kingdom , Italy , India , Russia , China , France , Dublin

Jude Samulski turns over AskBio CSO reins to Mansuo Shannon | North Carolina Biotechnology Center

Gene therapy legend R. Jude Samulski, Ph.D., co-founder and chief scientific officer of Asklepios BioPharmaceutical (AskBio) since the company was established in 2001, is leaving the CSO job but remaining on the company board.AskBio announced that Mansuo Shannon, Ph.D., becomes CSO effective today. Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, where she also served as CSO.

North-carolina , United-states , University-of-north-carolina , Germany , German , Eli-lilly , R-jude-samulski , Jude-samulski , Susumu-tonegawa , Sheila-mikhail , Samulski-askbio , Mansuo-shannon

Clinical trial data show investigational cancer vaccine may elicit lasting immune response in pancreatic cancer

Clinical trial data show investigational cancer vaccine may elicit lasting immune response in pancreatic cancer
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

United-states , American , Vinodp-balachandran , Roche-group , Pathogenesis-program , Pancreatic-cancer-research , Memorial-sloan-kettering-cancer-center , American-association-for-cancer-research , Davidm-rubenstein-center , Genentech , American-association

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer -April 07, 2024 at 02:00 pm EDT

Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran continue to show polyspecific T cell responses up to three...

California , United-states , Germany , San-diego , American , Fosun-pharma , Vinod-balachandran , Globenewswire-inc , American-association-for-cancer-research , Genentech-inc , Pfizer , Memorial-sloan-kettering-cancer-center

Three-year Phase 1 Follow-Up Data for mRNA-based

Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122,...

United-states , California , Germany , San-diego , American , Vinod-balachandran , Fosun-pharma , American-association-for-cancer-research , Roche-group , Genentech , Pfizer , Memorial-sloan-kettering-cancer-center

BioNTech SE: Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

BioNTech SE: Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United-states , San-diego , California , Germany , American , Fosun-pharma , Vinod-balachandran , Dennis-riedl , Roche-group , American-association-for-cancer-research , Memorial-sloan-kettering-cancer-center , Genentech

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

San-diego , California , United-states , Germany , American , Vinod-balachandran , Fosun-pharma , Pfizer , Memorial-sloan-kettering-cancer-center , Genentech , Roche-group , American-association-for-cancer-research

Ribometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024

Ribometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San-antonio , Texas , United-states , San-diego , California , North-carolina , American , Chris-railey , Michael-solomon , Jessica-sorrentino , Society-for-melanoma-research , Roche-group

Investegate | Company Announcement

Investegate announcements from Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

Germany , California , United-states , San-diego , American , Fosun-pharma , Vinod-balachandran , Roche-group , Memorial-sloan-kettering-cancer-center , American-association-for-cancer-research , Pfizer , Genentech

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer -April 07, 2024 at 02:00 pm EDT

Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran continue to show polyspecific T cell responses up to three...

San-diego , California , United-states , Germany , American , Vinod-balachandran , Fosun-pharma , Memorial-sloan-kettering-cancer-center , Roche-group , American-association-for-cancer-research , Pfizer , Genentech-inc